SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 1)
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)
DEPOMED, INC.
------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, NO PAR VALUE
------------------------------------------------------------------------------
(Title of Class of Securities)
249908104
------------------------------------------------------------------------------
(CUSIP Number)
DONALD G. DRAPKIN
35 E. 62nd St.
New York, NY 10021
(212) 572-8440
------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 18, 2000
------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check
the following box [ ]
NOTE: Schedules filed in paper format shall include a signed
original and five copies of the schedules, including all exhibits. See Rule
13d-7 for other parties to whom copies are to be sent.
CUSIP No. 249908104
------------------------------------------------------------------------------
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON.
Donald G. Drapkin
------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
------------------------------------------------------------------------------
3. SEC USE ONLY
------------------------------------------------------------------------------
4. SOURCE OF FUNDS
PF
------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e): [ ]
------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
USA
------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER 516,500
SHARES --------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER 0
OWNED BY EACH --------------------------------------------------------
REPORTING 9. SOLE DISPOSITIVE POWER 516,500
PERSON WITH: --------------------------------------------------------
10. SHARED DISPOSITIVE POWER 0
------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
516,500
------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.2%
------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON
IN
------------------------------------------------------------------------------
This Amendment No. 1 to Schedule 13D (this "Amendment") is being
filed pursuant to Rule 13d-2(a) of the Rules and Regulations under the
Securities Exchange Act of 1934, as amended (the "Act"), on behalf of
Donald G. Drapkin with respect to the common stock, no par value (the
"Common Stock"), of Depomed, Inc., a California corporation (the
"Company"). This Amendment amends the Schedule 13D originally filed by Mr.
Drapkin on October 13, 2000 (the "Initial Schedule 13D").
The Schedule 13D previously filed is hereby amended by the addition
of the following information:
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
As of October 19, 2000, Mr. Drapkin has invested $2,205,333 of his
personal funds to acquire shares of Common Stock.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a)-(b) As of June 30, 2000, based on information provided by the
Company, there were 7,189,363 shares of Common Stock outstanding. Mr.
Drapkin is currently the beneficial owner of 516,500 shares of Common
Stock, representing 7.2% of the Common Stock then outstanding. Mr. Drapkin
has the sole power to vote and dispose of the shares of Common Stock held
by him.
(c) Other than the transactions described in Item 5 of the Initial
Schedule 13D or set forth in the table below, there were no transactions by
Mr. Drapkin with respect to shares of Common Stock during the past 60 days.
The following table sets forth transactions in shares of Common
Stock effected by Mr. Drapkin during the past 60 days not previously
reported in the Initial Schedule 13D:
Date Nature of Transaction Number of Shares Price per Share
---- --------------------- ---------------- ---------------
10/6/00 Purchase 7,400 $4.00
10/6/00 Purchase 1,000 $3.875
10/6/00 Purchase 500 $4.0625
10/6/00 Purchase 600 $3.9375
10/6/00 Purchase 11,000 $4.125
10/16/00 Purchase 1,600 $4.25
10/16/00 Purchase 1,000 $4.00
10/16/00 Purchase 500 $4.375
10/16/00 Purchase 14,900 $4.50
10/17/00 Purchase 3,500 $4.6875
10/17/00 Purchase 16,300 $4.4375
10/17/00 Purchase 200 $4.375
10/17/00 Purchase 200 $4.5625
10/18/00 Purchase 2,100 $4.6875
10/18/00 Purchase 10,000 $4.625
10/18/00 Purchase 4,400 $4.75
10/19/00 Purchase 3,200 $4.875
10/19/00 Purchase 3,500 $4.9375
10/19/00 Purchase 6,000 $5.00
10/19/00 Purchase 2,500 $4.75
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: October 23, 2000
/s/ Donald G. Drapkin
--------------------------
Donald G. Drapkin
